Discovery calls: cost and pricing breakdown for 2026 for healthcare and life sciences in North America
Real-world costs of running discovery calls — tools, people, and services — with the trade-offs between each spend line. Written for commercial leaders at healthtech, medtech, and life-sciences companies in North America.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install discovery calls has to be shaped to that reality from day one.
Budgeting for discovery calls without seeing real numbers is guesswork. Here are the ranges we see across the fifty-odd engagements we have run.
A minimum-viable discovery calls setup — one operator, one core tool, one signal source — runs $2–5k monthly and produces defensible discovery-to-opportunity conversion inside a quarter.
A production discovery calls setup — dedicated owner, primary plus secondary tooling, warmed sending infrastructure — is in the $10–25k monthly range depending on volume.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Discovery calls is only useful here when it is pointed at both constraints at once.
An enterprise deployment — multi-region, governance overhead, integrated data — is $50k+ monthly, with headcount often the largest line rather than software.
Where teams overspend: buying tools that solve edge cases they do not yet have. Where teams underspend: hiring the operator who owns the model.
Rule of thumb: for every dollar spent on tooling, budget two dollars on the human who runs it. Inverting that ratio is the classic reason for wasted spend.
The single largest hidden cost is reading a script instead of running a diagnosis — because the cash cost is invisible and the opportunity cost is enormous.
Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing discovery calls deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · North America — answered
- Does discovery calls work for healthcare and life sciences in North America?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed. The healthcare teams that install this get past procurement instead of dying in it.
- How much does discovery calls cost to start?
- A defensible minimum is $2–5k monthly for tooling and one part-time operator.
- What drives discovery calls cost at scale?
- Headcount more than software. Enterprise deployments are usually 60%+ people.
- Where do teams overspend?
- On tools that solve edge cases they do not yet have.
- What is the hidden cost of discovery calls?
- Reading a script instead of running a diagnosis — invisible on the invoice, expensive on the P&L.
- What is the North America-specific pitfall when running discovery calls for healthcare?
- Importing a playbook that was built for another market. In North America, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · north america